Qiagen
Qiagen N.V., a leading global provider of sample and assay technologies, is headquartered in Germany (DE) and operates extensively across Europe, North America, and Asia. Founded in 1984, Qiagen has established itself as a key player in the biotechnology industry, focusing on molecular diagnostics, applied testing, and academic research. The company offers a diverse range of core products and services, including nucleic acid extraction kits, PCR reagents, and bioinformatics solutions, all designed to enhance the efficiency and accuracy of laboratory workflows. Qiagen's innovative technologies, such as its proprietary QIAamp® and QIAcube® systems, set it apart in the market. With a strong commitment to advancing precision medicine and diagnostics, Qiagen has achieved significant milestones, including partnerships with major healthcare institutions and a robust portfolio of patents. Its position as a trusted leader in the life sciences sector underscores its dedication to improving global health outcomes.
DitchCarbon Score
How does Qiagen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Qiagen's score of 63 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Qiagen's reported carbon emissions
In 2023, QIAGEN N.V. reported total greenhouse gas emissions of approximately 351,424,000 kg CO2e, comprising 13,375,000 kg CO2e from Scope 1, 3,930,000 kg CO2e from Scope 2, and a significant 334,119,000 kg CO2e from Scope 3 emissions. This reflects a commitment to reducing its carbon footprint across all scopes. The company has set ambitious targets as part of its climate strategy. QIAGEN aims to achieve net-zero greenhouse gas emissions across its value chain by 2050, using 2020 as the baseline year. Near-term goals include a 42% reduction in absolute Scope 1 and 2 emissions by 2030, and a 25% reduction in Scope 3 emissions related to business travel, use of sold products, and end-of-life treatment of sold products within the same timeframe. Additionally, QIAGEN is committed to ensuring that 67% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027. Long-term, QIAGEN aims for a 90% reduction in absolute emissions across all scopes by 2050, reinforcing its commitment to sustainable practices in the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Qiagen is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
